Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience

CONCLUSION: Our findings indicate that low pre-LD ALC with high percent reduction from pre-A to pre-LD was associated with inferior survival outcomes, particularly OS, in patients who received SOC …